Table 1 Patients’ characteristics. Demographics, uveitis diagnosis, and steroid treatment regimen of patients.
Patient Age Gender Race Eye Diagnosis Steroid
1 17 F Caucasian Left JIA with chronic anterior uveitis
Ocular hypertension/steroid response Loteprednol drops 2 52 F Caucasian Right Iridocyclitis, both, CRAO right
Ocular hypertension right None
3 72 M Caucasian Right Chronic Anterior Uveitis with CME
Severe uveitic glaucoma Loteprednol drops
4 16 M Caucasian Left Pars planitis
Ocular hypertension/steroid response Sub-tenon triamcinolone acetonide 4 16 M Caucasian Right Pars planitis
Ocular hypertension/steroid response Sub-tenon triamcinolone acetonide 5 23 F Caucasian Right Pars planitis
Ocular hypertension/steroid response Fluocinolone acetate implant 5 23 F Caucasian Left Pars planitis
Ocular hypertension/steroid response Fluocinolone acetate implant
6 89 M Asian Right Panuveitis
Severe uveitic and PXF glaucoma Prednisolone acetate drops 7 13 F Caucasian Right Pars planitis
Ocular hypertension/steroid response Fluocinolone acetate implant 7 13 F Caucasian Left Pars planitis
Ocular hypertension/steroid response Fluocinolone acetate implant 8 74 F Caucasian Right Ocular lichen planus with iritis
Severe uveitic glaucoma/steroid response Fluorometholone drops 8 74 F Caucasian Left Ocular lichen planus with iritis
Severe uveitic glaucoma/steroid response Fluorometholone drops 9 18 M Caucasian Right Chronic anterior uveitis, idiopathic
Ocular hypertension/steroid response Sub-tenon triamcinolone acetonide
10 43 F African
American Left Sarcoidosis with Panuveitis
Ocular hypertension/steroid response Prednisolone acetate drops Sub-tenon triamcinolone acetonide 11 61 M Caucasian Left Immune reconstitution uveitis with cystoid
macular edema
Ocular hypertension/steroid response
Sub-tenon triamcinolone acetonide
12 79 F African
American Left Chronic anterior uveitis, post-operative
Severe uveitic glaucoma/steroid response Prednisolone acetate drops
Patient Age Gender Eye Lens Status IOP (mmHg) Medications IOP at goal Follow-up Time (months) Max Pre-op Goal Last* Reduction† Pre-op Post-op Reduction
1 17 F Left Phakic 40 20 21 44 -120% 5 5 0 No 1§
2 52 F Right Phakic 42 40 21 16 60% 3 1 -2 Yes 18
3 72 M Right Pseudophakic 32 24 16 13 46% 4 4 0 Yes 16
4 16 M Left Phakic 40 28 21 13 54% 5 0 -5 Yes 12
4 16 M Right Phakic 38 30 21 14 53% 5 3 -2 Yes 11
5 23 F Right‖ Phakic 22 7‡ 21 10 -43% 3 1 -2 Yes 6
5 23 F Left Pseudophakic 44 24 21 11 54% 3 1 -2 Yes 5
6 89 M Right Pseudophakic 30 30 12 26 13% 3 2 -1 No 17
7 13 F Right Pseudophakic 36 28 21 15 46% 3 0 -3 Yes 14
7 13 F Left Pseudophakic 36 32 21 15 53% 3 0 -3 Yes 14
8 74 F Right Pseudophakic 32 32 15 26 19% 4 4 0 No 7
8 74 F Left Pseudophakic 36 32 15 41 -28% 4 4 0 No 3
9 18 M Right Pseudophakic 43 43 21 13 70% 4 1 -3 Yes 12
10 43 F Left Phakic 36 34 21 18 47% 3 1 -2 Yes 11
11 61 M Left‖ Phakic 30 25 21 38 -52% 2 2 0 No 0.5§
12 79 F Left Pseudophakic 32 20 18 33 -65% 4 4 0 No 6
Table 2 Intraocular pressure and medications reduction at last follow up visit. IOPs and IOP lowering medications of patients before and after the surgery.
*
IOP at last follow-up visit or the last visit prior to further surgical intervention
†
Percent reduction calculated from the pre-operative IOP
‡
The decision to operate on this patient was based on a visually-significant cataract and prior maximum IOP of 22.
§
Follow-up time was limited if the patient required a second surgery prior to post-operative month 3. IOPs were only included in the data set up until the second surgery.
‖
